| INTRODUCTION
Phaeochromocytomas (PCC) and paragangliomas (PGL) are tumors of chromaffin cells that often produce and secrete catecholamines and their metabolites. PCC occur within the adrenal medulla and PGL present as tumors of the extra-adrenal sympathetic nervous system, occurring in the head and neck, chest, abdomen, or pelvis. 1 These tumors can present either as benign, in the majority of the cases, or may be malignant.
There are currently no established criteria for establishing PCC/PGL as malignant apart from the presence of metastases at diagnosis. 2 In cases where metastases are found, surgery is usually of limited therapeutic value and other therapeutic modalities have been proposed. These include chemotherapy, external radiotherapy, radiofrequency ablation therapy, tyrosine kinase receptor inhibitors, and radionuclide therapy. [2] [3] [4] [5] [6] (131)I-metaiodobenzylguanidine (MIBG) is a frequently used treatment for advanced neuroendocrine tumors, leading to symptomatic control, stabilization of disease progression, and increased overall survival. 7 Peptide Receptor Radionuclide treatment (PRRT) with radiolabeled somatostatin analogues have also been used in the treatment of neuroendocrine tumors. However, data on PRRT use in metastatic PCCs and PGLs are limited. There are a few reports for the treatment of these patients with PRRT, and although this therapy seems effective, it is not reported to be as effective as in other subtypes of neuroendocrine tumors. [8] [9] [10] To date, there is no study comparing (131)I-MIBG treatment and PRRT in the management of patients with progressive PCCs and PGLs.
The aim of the present study is to retrospectively compare MIBG and PRRT treatment in patients with metastatic/progressive PCCs and PGLs, in terms of overall survival, progression free survival, event free survival, response to treatment, and toxicity.
| MATERIALS AND METHODS

| Population
This was a retrospective study of the patients with locally advanced/ metastatic progressive PGLs and PCCs treated in our department during the period 1998-2013. All patients were characterized as "metastatic" either during follow-up after initial surgery, or when metastases were present at tumor diagnosis.
The decision for commencement of radionuclide therapy was made when negative for avidity to somatostatin receptor agonist tracers. In view of this patients in our series were not routinely scanned for both modalities throughout the entire study period. However, during the years of the study period imaging with somatostatin receptor agonist tracers has increased in our department as a result of the increased avidity that has been shown in patients with PGLs.
Patients with non-progressive and symptomatically controlled disease, surgically treatable primary or metastatic disease, as well as patients with renal failure or bone marrow disease were excluded from radionuclide treatment.
Patient age, sex, tumor type, tumor location, genetic background, the presence of metastasis on diagnosis, the operability, the extent of metastatic disease, the functionality of the tumor, and the administration of additional therapies were recorded.
As this was a retrospective audit of practice, research ethical approval was not required.
| Radionuclide therapy protocol 2.3.1 | (131)I-MIBG
All patients had a pre-therapy (123)I-MIBG scan to assess appropriate uptake of tracer in the sites of known disease. The administered activity of (123)I-MIBG was 220 MBq with scans performed on a dualhead gamma camera using a low-energy high-resolution collimator 24 h after injection. between 6 weeks and 3 months after the completion of treatment courses and then every 4-6 months. Tumor response to treatment was evaluated retrospectively according to the RECIST 1.1 criteria. All imaging were reviewed by an experienced radiologist.
Progression free survival was defined as the interval between the first radionuclide treatment and the radiological progression of the disease, or death related to the disease. Time to progression was also calculated and was defined as interval between the first radionuclide treatment and the radiological progression of the disease without taking death into account. Finally, as we did not have any consistent data on quality of life after the treatment, we calculated event free survival, which was defined as the interval between the first radionuclide treatment and any event related to radiological progression, major toxicity, any major disease related event that lead to hospitalization or death. As many patients were subjected to multiple treatments, progression free survival, time to progression, event free survival, and response to treatment were calculated individually for every treatment and not per patient. Overall survival was calculated for every patient and was defined as the interval between the first radionuclide treatment and death.
| Treatment toxicity
Minor side effects, during or after treatments, were not recorded. Data for major side effects of treatment, in terms of haematological and renal toxicity, were collected. Renal and haematological toxicity were graded, according to the National Cancer Institute Toxicity Criteria.
| Statistical analysis
Results are expressed as mean ± standard deviation (SD). Comparison between groups was performed using the Chi-Square test for qualitative data and the unpaired t-test for quantitative data. Overall Kaplan-Meier survival curves, progression-free Kaplan-Meier survival curves, time to progression curves and event free survival curves were generated for each group and compared with a log-rank test for proportional hazards and the Breslow test if differences were depicted early in the follow up period. A P-value smaller than 0.05 was considered as significant.
| RESULTS
During the period 1998-2013, we found 22 patients with progressive metastatic paragangliomas or phaeochromocytomas that were referred for radionuclide therapy with either (131)I-MIBG, (90)Y-DOTATATE, and (177)Lu-DOTATATE. The mean age at diagnosis was 46.9 ± 15 years. Patient characteristics are summarized in Table 1 . PGLs were subjected to 21 treatments, from which 13 were with PRRT and 8 were with (131)I-MIBG. The above data, cumulative dosage, treatment cycles, and total number of treatments are summarized in Table 2 .
Patients were followed up continuously in our departments' outpatient clinic. The follow-up period ranged from 6 to 122 months (mean 38.7 months) for patients that eventually died and 2-134 months (mean 56.4 months) for patients that were alive at the end of the study period. We had no patients lost in follow-up. Table 5 .
| DISCUSSION
The management of patients with metastatic PCCs and PGLs can be challenging. Although multiple therapeutic modalities exist, including chemotherapy, external beam radiation, tyrosine kinase inhibitors, and surgery in some cases, radionuclide treatment has been shown to be most effective in the treatment of those patients. [10] [11] [12] Traditionally, (131)I-MIBG has been shown to have a high tracer affinity for these tumors. 13 During the last decades, radionuclide imaging with radiolabeled somatostatin analogues has been shown to be an alternative option, as well, leading to respective therapeutic interventions. 8 (90)Y-(DOTATOC), (90)Y-DOTATATE, and (177)Lu-DOTATATE are the main peptide receptor radionuclide treatment used to date. [8] [9] [10] 14 The literature is scarce in studies comparing these two agents in neuroendocrine tumors in general, while there is no study to date However, theirs study did not concern metastatic disease as only one of the nine patients had distant metastasis. 10 In our study, we have shown a response in 11 of 11 (100%) treatments with (90)Y-DOTATATE and a mean PFS of 43 months.
However, this result should be interpreted with caution, as one of the patients in this group had initially presented with a locally inoperable and symptomatic PGL, received radionuclide treatment and later developed metastases. In addition, in our study, response to treatment was evaluated 6 weeks to 3 months after treatment and according to RECIST 1.1 criteria, as opposed to WHO and other criteria used in other studies. PCCs. Some patients showed progression later in their follow up and the overall response rate became 66%. 1 An interesting finding in our study is that efficacy of treatment seems to be different between patients with PCCs and PGLs,
suggesting that these two pathologies should probably not be treated scintigraphy is more sensitive than (131)I-MIBG imaging in the detection of extra-adrenal phaeochromocytomas using (99 m)Tc-HYNIC-TOC as a tracer. 15 In the same time, Koopmans et al have reported similar data for the affinity of head and neck paragangliomas using (111)In-octreotide vs (123)I-MIBG. 16 In keeping with this, Jalil et al has reported a sensitivity of 88% for the detection of unilateral
PCCs as opposed to 64% for extra adrenal tumors using (131)I-MIBG scintigraphy. 19 Bhatia et al. 20 have published similar results (85% for PCCs and 58% for PGLs) with (123)I-MIBG scintigraphy.
The single most important finding of our study was that patients with metastatic PGLs seem to have a better prognosis when receiving PRRT treatment instead of (131)I-MIBG. In view of this it seems more rational that these patients be preferentially scanned for somatostatin receptor agonist tracer avidity and only when no avidity is found, for (123)I-MIBG avidity. However, the same cannot be said for patients with metastatic PCCs, direct comparison between the two treatments could not be made in our study.
A major limitation of our study includes the retrospective nature of the data collection. In addition, the PRRT group included only a small number of patients treated with (177)Lu-DOTATATE, since it has only been available in our unit since 2011. In the (131)I-MIBG treatment group dosage protocols varied during the period studied and as a result, there is heterogeneity in the treatment protocol between patients. Our unit's protocols did not include high dosage treatments, which has been reported to be quite effective in neuroendocrine tumors in general and PGLs/PCCs in particular. Recent data have also speculated the role of a combination of these treatment modalities, in order to be able to maximize efficiency and limit toxicity, which we did not address in our study. 21, 22 Finally, we did not have comparative data on symptomatic/biochemical response or quality of life after the 
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